This article reviews the basic and clinical features of heart disease associated with carcinoid syndrome, with an emphasis on its principal imaging modalities.
Clinical Presentation (Carcinoid Syndrome)
Clinical presentation of carcinoid tumours may result either from the primary tumour and its metastasis or from the carcinoid syndrome. Symptoms related to tumour growth and metastasis depends on the primary site of the tumour. For example, abdominal pain and intestinal obstruction may be the presenting symptoms of a small bowel carcinoid tumour, whereas symptoms of bronchial obstruction are typically found in a tumour of bronchopulmonary origin.
Carcinoid syndrome results from the secretion, by the primary tumour and its metastases, of growth factors, polypeptides, and vasoactive substances, mostly serotonin, tachykinin, histamine, kallikrein, and prostaglandins, into the systemic circulation. Typical manifestations of the carcinoid syndrome are episodic facial and upper chest flushing, chronic severe diarrhoea, bronchospasm, hypotension, venous telangiectasia, and cardiac valvular lesions. The diagnosis of carcinoid syndrome is usually confirmed by elevated blood serotonin concentration or elevated urine 5hydroxyindoleacetic acid excretion. Tumours that originate from the embryogenic foregut organs (bronchus, stomach, and duodenum) often lack the aromatic amino acid decarboxylase that converts 5-hydroxytryptophan to serotonin and thus tend to secrete less serotonin than tumours that originate from midgut organs (jejunum, ileum, appendix, and ascending colon). Hindgut organs (transverse and descending colon, sigmoid, and rectum) also rarely produce bioactive hormones [4] . Furthermore, circulating bioactive products are inactivated by the liver, which explains why intestinal carcinoids without hepatic metastases rarely cause hormonal symptoms. When metastases are present, the bioactive substances are secreted directly in the systemic circulation, bypassing the liver. In contrast, carcinoid tumours with direct access to the systemic circulation, like bronchopulmonary carcinoid tumours, can cause the syndrome independently of metastatic disease.
Carcinoid heart disease develops in up to 50% of patients with long-standing carcinoid syndrome [5] and remains a major cause of morbidity and mortality. Advanced valvular changes are associated with increased mortality, with a 5-year survival rate of 30% in patients with severe valvular disease compared with 75% in patients with normal or slightly affected valves. Even though patients with severe carcinoid heart disease more frequently die from tumour progression than from right-heart failure, valvular disease has proved to be a reliable prognosis marker, which indicates that valve changes correlate with the primary tumour's severity and duration [6] .
Serotonin is thought to be one of the major etiologic vasoactive substances for valvular lesions because higher serotonin plasma concentration correlates with higher rates of valvular pathology [7] . Serotonin, and to a lesser extent, other agents with fibroblast-proliferative action such as tachykinins and transforming growth factor b, induces irreversible endocardial fibrosis of valvular cusps and leaflets, which results in reduced motion and, eventually, valvular dysfunction (regurgitation and stenosis). Smooth-muscle cells, myofibroblasts, and endothelial cells also proliferate and form a complex and thick fibrotic-like tissue called the carcinoid plaque [8] . Because the lungs metabolize serotonin and other humoral substances, the left heart is often free of fibrosis. In fact, mitral and aortic valvular dysfunction occurs in fewer than 10% of patients with carcinoid heart disease, and it is associated with right-to-left shunt as well as primary bronchial carcinoids or a rare cardiac complication, myocardial metastasis. In a report that studied the frequency of the different hemodynamically significant valve anomalies found in carcinoid heart disease, 132 patients with carcinoid syndrome underwent echocardiographic study, including Doppler. Among the 74 patients with echocardiographic evidence of carcinoid heart disease, all the patients had tricuspid regurgitation, which was moderate to severe in 90% of them. Indirect echocardiographic findings were consistent with some degree of associated tricuspid stenosis. Pulmonary valve regurgitation and stenosis were found in 81% and 53%, respectively [9] . Patients with aggressive carcinoid tumours may present with symptoms of acute severe valvular dysfunction, most commonly, tricuspid insufficiency. The differential diagnosis of causes of severe tricuspid regurgitation includes functional tricuspid regurgitation after right ventricular dilatation, rheumatic fever, infective endocarditis, myxomatous degeneration, papillary muscle rupture, Ebstein anomaly, connective tissue diseases (eg, Marfan syndrome and marantic endocarditis in systemic lupus erythematosus or rheumatoid arthritis). Anorectic drugs (eg, fenfluramine and dexfenfluramine), and ergot derivatives, including drugs used in the treatment of migraine (eg, ergotamine) and Parkinson (eg, pergolide), are also associated with valvular damages. Serotonin is thought to play a central role in the pathogenesis of carcinoid syndrome as well as drug-induced valvular disease, which explains why imaging and pathologic features resemble in both pathologies [9e11].
Imaging Modalities of Carcinoid Heart Disease

Plain Chest Film
The plain radiograph is frequently abnormal in patients with hemodynamically significant valvular heart disease. Findings are nonspecific and demonstrate right-sided heart failure. Cardiomegaly, mostly right-sided heart dilatation, is a common finding. Decreased pulmonary vascularity is occasionally noted in the presence of severe pulmonary valve stenosis. Metastatic pleural plaques and associated pleural effusions may be noted on a plain chest radiograph in late-stage disease. The plaquelike deposits on the heart valves do not calcify and, therefore, are not seen on a plain radiograph. 
Doppler Echocardiography
Two-dimensional echocardiography is an excellent initial imaging modality to evaluate valvular dysfunction and is recommended in all patients with carcinoid syndrome, whether or not they present with symptoms of heart failure. Typical echocardiographic findings of advanced carcinoid heart disease include thickening and reduced mobility of tricuspid valve leaflets, chordae, and papillary muscles, which show incomplete coaptation of the valve that results in severe regurgitation and, less frequently, stenosis (Figure 2 ). Further findings include the loss of the normal concave curvature of the leaflets and the fusion and shortening of the chordae, associated with a greater degree of retraction. In most severe cases, leaflets are fixed and immobile. Pulmonary valve anomaly is also commonly noted on echocardiographic images. Immobility and retraction of the pulmonary cusps, and pulmonary annular constriction, with varying degrees of regurgitation and stenosis, represent the classic findings. However, pulmonary cusps retraction may render pulmonary 
Magnetic Resonance Imaging and CT
Both magnetic resonance imaging (MRI) and CT add further information in the evaluation of cardiovascular structures, for example, valve morphology and chamber size, particularly when involving the right heart. In carcinoid heart disease, MRI and CT can demonstrate important right-heart dilatation, including pulmonary arteries; flattening; and paradoxical motion of the interventricular septum, which are consequences of right-volume overload. Thickened and retracted tricuspid and pulmonary valves may also be noted. Pericardial effusion is present in 10% of cases [12] . In addition, cinematic and velocity-encoded cinematic MRI sequences can precisely assess valve motion and dysfunction, and allow quantitative analysis of tricuspid and pulmonary valves regurgitation and stenosis. In advanced disease, the tricuspid valve and, to a lesser extent, the pulmonary valve usually appear fixed and retracted in an open position throughout the entire cardiac cycle, which leads to severe regurgitation (Figure 3 ). Delayed enhanced MRIs after gadolinium contrast administration may demonstrate late gadolinium hyperenhancement of both tricuspid and pulmonary valves, but this phenomenon is not essential to the diagnosis of carcinoid heart disease (Figure 4 ).
Summary
In patients with carcinoid syndrome, cardiac imaging is crucial in the assessment of valvular involvement. Doppler echocardiography is presently the diagnosis modality of choice, but cardiac MRI appears promising to complete dynamic heart evaluation. Cardiac MRI offers many advantages. With the ability to scan in any plane, it allows accurate evaluation of heart structures. Cinematic MRI with velocity-encoded cinematic MRI sequences allows quantification of heart valves dysfunction. Finally, delayed gadolinium enhancement appears as a potentially promising modality to detect fibrous deposits on endocardium and to grade its severity. Carcinoid heart disease can present with a wide range of radiologic findings, which makes its diagnosis challenging. Therefore, the diagnostic approach of suspected carcinoid heart disease should include several imaging modalities, which range from a simple plain chest radiograph to gadolinium-enhanced MRI.
